Do results of the T-SPOT.TB interferon-γ release assay change after treatment of tuberculosis? - 08/08/11
Summary |
Background |
Interferon-gamma (IFN-γ) production by lymphocytes exposed to antigens specific of Mycobacterium tuberculosis has been shown to correlate with antigen load and disease activity.
Aim of study |
To determine whether treatment of tuberculosis (TB) led to a decrease and/or a reversion of results of a IFN-γ release assay (T-SPOT.TB, Oxford Immunotec, UK) and thus if T-SPOT.TB could be used to monitor response to treatment.
Methods |
Qualitative and quantitative analysis (SFUs: spot-forming units) of T-SPOT.TB® in HIV-negative patients with TB, during initial 2 weeks of treatment (T0), at end of treatment (TE) and 6 months later (TE+6).
Results |
Mean SFU (SD) was 75 (58; n=62) at T0, 46 (55; n=55) at TE, and 33 (46; n=41) at TE+6; positive rate was 98%, 93% and 98%, respectively. SFUs (paired samples, n=36) decreased significantly between T0 and TE; 2 reversions occurred between T0 and TE (6%), but none between TE and TE+6. Of 6 patients (17%) with an increase in SFUs between T0 and TE, 5 had a favourable outcome at TE and TE+6.
Conclusion |
Decrease in SFUs under treatment suggests a relationship with antigen load; however, persisting high SFUs were not predictive of unfavourable outcome and test reversion was rare.
This trial was registered at www.clinicaltrials.gov (NCT00595907).
Le texte complet de cet article est disponible en PDF.Keywords : Tuberculosis, Monitoring treatment, Interferon-gamma release assay, Cytokine release
Plan
Vol 103 - N° 1
P. 30-34 - janvier 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?